Updated:
SHL Medical
SHL Medical, chaired by Christian Scherer, is the private Zug-based manufacturer whose autoinjectors dominate global emergency and chronic care drug...
SHL Medical
SHL Medical was founded in 1989 and is headquartered in Zug, Switzerland. Christian Scherer serves as Chairman of the privately held industrial group that has scaled to become the world's largest manufacturer of autoinjectors by volume. The firm's origin traces to supplying precision injection-molded components, before a strategic pivot into complete drug delivery devices that now define the company. The company operates across the full value chain — in-house industrial design, tooling, high-volume manufacturing, and final assembly — serving pharmaceutical and biotech clients globally. Its core asset-class exposure is industrial real assets and specialized contract manufacturing. Stage coverage is typically late-stage and commercial-supply, partnering with pharma companies after drug approval. Key relationships include long-term supply agreements with Amgen and other top-20 pharma firms; its devices are used for emergency anaphylaxis treatment, chronic-biologic delivery, and high-viscosity injectables across North America, Europe, and Asia. SHL Medical operates production facilities in Taiwan and recently expanded its footprint with a new US manufacturing site in Charleston, South Carolina. The firm added capacity to support growing demand for its autoinjector platforms, notably the Molly and Maggie device families. May 2024: The Charleston, South Carolina manufacturing site achieved commercial readiness, expanding US-based final assembly and testing capacity (per the firm, May 2024). The company remains privately held with no known adjacent fund vehicles or co-investment platforms. SHL Medical is structurally distinct from a typical private equity or venture-backed industrial asset. It functions as an owner-operated, family-controlled industrial manufacturer working on decade-long contracted supply cycles with global pharma — a capital-intensive moat that provides the firm with sticky, recurring revenue streams and deep integration into regulated pharmaceutical supply chains.
General information
Firm type
Asset Manager
Year founded
1989
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Zug
Corporate office
Zug, Switzerland
Principals
Christian Scherer
Chairman
Sector focus
Frequently asked questions
What does SHL Medical actually manufacture?
SHL Medical designs and mass-produces autoinjectors, pen injectors, and advanced drug delivery systems. Its devices handle high-viscosity biologics and are used for emergency treatments like anaphylaxis as well as chronic therapies. The company's Molly and Maggie autoinjector platforms are among the industry's most widely deployed.
Who are SHL Medical's major pharmaceutical clients?
While specific customer contracts are confidential, SHL Medical has publicly acknowledged long-term supply relationships with Amgen and other top-20 global pharmaceutical firms. Its autoinjectors carry blockbuster biologic drugs and are used in both branded and generic drug delivery programs worldwide.
Is SHL Medical a publicly traded company or a family office?
SHL Medical is a privately held, industrial manufacturer and is not publicly traded. It operates as an owner-managed group with no disclosed family-office structure, venture arm, or co-investment vehicle. The firm reinvests capital into its own manufacturing capacity and device platform development.
Where does SHL Medical operate its manufacturing sites?
Production is anchored in Taiwan, where the firm operates large-scale molding and assembly campuses. In 2024, SHL Medical expanded its footprint into the US with a new commercial-scale site in Charleston, South Carolina, adding domestic final assembly, labeling, and testing capacity for North American pharma supply chains.
How is SHL Medical structured compared to a typical contract manufacturer?
Unlike a generic contract manufacturer, SHL Medical owns its autoinjector platform IP and performs in-house industrial design, tooling, regulatory support, and final assembly. This vertically integrated model creates deep operational lock-in with pharmaceutical clients and differentiates the firm from low-cost, build-to-print competitors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: